EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Emerging clinical applications of ADAR based RNA editing

Joseph Rainaldi iD, Prashant Mali, Sami Nourreddine iD

Stem Cells Translational Medicine · 19.05.2025 · 14 (5)

DOI: 10.1093/stcltm/szaf016 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Stem Cells Translational Medicine, online erschienen am 26.05.2025. Verfasst von Joseph Rainaldi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, University of California San Diego, La Jolla, CA 92093, United States. Hauptthemen laut MEDLINE: RNA Editing, Adenosine Deaminase, RNA-Binding Proteins. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIH HHS, NHGRI NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RNA editing via adenosine deaminases acting on RNA (ADARs) offers precise and reversible modifications at the RNA level, complementing traditional DNA-targeting therapies. ADAR enzymes catalyze the conversion of adenosine to inosine within double-stranded RNA, influencing critical cellular processes such as translation, splicing, and RNA stability. Utilizing endogenous ADARs guided by exogenous guide RNAs enables site-specific RNA editing without the need for transgenic editor expression, minimizing immunogenicity, and enhancing control over gene expression. Towards addressing the challenges in ensuring specificity, optimizing delivery methods, and navigating regulatory landscapes, ongoing innovations in guide RNA design, delivery technologies, and computational modeling are propelling the field forward. Already, initial clinical advancements are demonstrating the potential of ADAR-mediated RNA editing in treating human diseases. Collaborative efforts among researchers, clinicians, and industry partners are overcoming existing hurdles, progressively positioning ADAR-mediated RNA editing to revolutionize personalized medicine and provide effective treatments for a wide array of historically intractable diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA EditingAdenosine DeaminaseRNA-Binding ProteinsHumansAnimals

Substanzen

Adenosine DeaminaseRNA-Binding ProteinsADAR protein, human

Autor:innen und Institutionen

  • Department of Bioengineering, University of California San Diego, La Jolla, CA 92093, United States.
  • Biomedical Sciences PhD Program, University of California San Diego, La Jolla, CA 92093, United States.

ORCID-Profile: Joseph Rainaldi, Sami Nourreddine

Förderung

  • NIH HHS
  • NHGRI NIH HHS
  • NIGMS NIH HHS
  • U.S. Department of Defense

Zitieren

APA

Rainaldi, J., Mali, P., & Nourreddine, S. (2025). Emerging clinical applications of ADAR based RNA editing. Stem Cells Translational Medicine, 14(5). https://doi.org/10.1093/stcltm/szaf016

Vancouver

Rainaldi J, Mali P, Nourreddine S. Emerging clinical applications of ADAR based RNA editing. Stem Cells Translational Medicine. 2025;14(5). doi:10.1093/stcltm/szaf016

BibTeX
@article{Rainaldi2025,
  author = {Rainaldi, Joseph and Mali, Prashant and Nourreddine, Sami},
  title = {Emerging clinical applications of ADAR based RNA editing},
  journal = {Stem Cells Translational Medicine},
  year = {2025},
  volume = {14},
  number = {5},
  doi = {10.1093/stcltm/szaf016}
}
Kostenlos starten →